Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
FDA Official Offers Advice on Regulatory Path for Companion Diagnostics
September 22, 2010
At an industry conference last week, a scientific reviewer at FDA's Office of In Vitro Diagnostics Device Evaluation and Safety discussed detailed strategies for navigating the regulatory process for Rx/Dx combination products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- With Companion Dx Guidance Nearing Release, FDA's Mansfield Offers Some 'Provisional' Advice
April 13, 2011 / Pharmacogenomics Reporter - FDA Top Officials Discuss Ongoing Efforts to Bring Agency Into Genomics Era
November 11, 2009 / Pharmacogenomics Reporter - Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
May 23, 2012 / Pharmacogenomics Reporter - Q&A: Diaceutics CEO Keeling Provides Personalized Rx-Focused Consultant's View of Industry Progress
February 22, 2012 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter